{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11"],"submitter":["Negash R"],"pubmed_abstract":["<h4>Introduction</h4>Feline Infectious Peritonitis (FIP) has historically been a fatal coronavirus disease in cats. In recent years, the therapeutic agent GS-441524, developed by Gilead Sciences, was found to be a successful treatment for FIP in most patients in clinical trials. However, this particular drug has remained stalled in the therapeutic pipeline, leaving patients and cat owners without a licensed medication. In the meantime, online social media platforms began to emerge, connecting cat owners with a community of citizen non-veterinary professionals sourcing unlicensed GS-441524.<h4>Methods</h4>This study prospectively followed participants (<i>N</i> = 141) that successfully completed 12 weeks of treatment, capturing their treatment experiences with self-administered GS-441524-li"],"journal":["Frontiers in veterinary science"],"pagination":["1377207"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11233523"],"repository":["biostudies-literature"],"pubmed_title":["Owner experience and veterinary involvement with unlicensed GS-441524 treatment of feline infectious peritonitis: a prospective cohort study."],"pmcid":["PMC11233523"],"pubmed_authors":["Jacque N","Li E","Novicoff W","Negash R","Evans SJM"],"additional_accession":[]},"is_claimable":false,"name":"Owner experience and veterinary involvement with unlicensed GS-441524 treatment of feline infectious peritonitis: a prospective cohort study.","description":"<h4>Introduction</h4>Feline Infectious Peritonitis (FIP) has historically been a fatal coronavirus disease in cats. In recent years, the therapeutic agent GS-441524, developed by Gilead Sciences, was found to be a successful treatment for FIP in most patients in clinical trials. However, this particular drug has remained stalled in the therapeutic pipeline, leaving patients and cat owners without a licensed medication. In the meantime, online social media platforms began to emerge, connecting cat owners with a community of citizen non-veterinary professionals sourcing unlicensed GS-441524.<h4>Methods</h4>This study prospectively followed participants (<i>N</i> = 141) that successfully completed 12 weeks of treatment, capturing their treatment experiences with self-administered GS-441524-li","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-19T01:07:25.466Z","creation":"2025-04-07T12:05:31.957Z"},"accession":"S-EPMC11233523","cross_references":{"pubmed":["38988986"],"doi":["10.3389/fvets.2024.1377207"]}}